Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors
| Autor: | Wan-Seok Kim, Il-Young Kweon, Soo-Hyun Kim, Dong-Wook Kim, Sa-Hee Park, Hyun-Gyung Goh, Dongho Kim, Jeong Lee |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Cancer Research Adolescent medicine.drug_class Dasatinib Fusion Proteins bcr-abl Mutation Missense Antineoplastic Agents medicine.disease_cause Tyrosine-kinase inhibitor Piperazines Young Adult hemic and lymphatic diseases Leukemia Myelogenous Chronic BCR-ABL Positive Republic of Korea medicine Missense mutation Humans Point Mutation Philadelphia Chromosome Protein Kinase Inhibitors Aged Salvage Therapy Mutation business.industry Point mutation Hematology General Medicine Middle Aged medicine.disease Protein Structure Tertiary Leukemia Thiazoles Imatinib mesylate Pyrimidines Treatment Outcome Oncology Nilotinib Drug Resistance Neoplasm Benzamides Cancer research Imatinib Mesylate Female business medicine.drug |
| Zdroj: | Hematological oncology. 28(2) |
| ISSN: | 1099-1069 |
| Popis: | We analysed the dynamic change of imatinib-resistant mutations in BCR-ABL kinase domain focusing on T315I mutation during dasatinib or nilotinib therapy. Fifty-five imatinib-resistant chronic myeloid leukaemia patients (32 patients with imatinib-resistant mutations and 23 patients without mutation) in different disease phases were treated with dasatinib (median 17.3 months) or nilotinib (median 6.8 months). Among the 32 patients with baseline mutation, mutations including M244V, G250E, E255K, M351T, H396R, S417Y, E450K and E459K disappeared in 8 patients and new mutations were detected in 9 patients, all of which were T315I. Among the 23 patients without baseline mutation, 4 patients showed newly developed mutations including T315I, T315I + E459K, M244V and F359V. The T315I was the most frequently detected mutation in imatinib therapy (16%, 9 of 55) as well as in dasatinib or nilotinib therapy (24%, 11 of 44). Patients with imatinib resistant baseline mutations had a higher rate of mutation development during dasatinib or nilotinib treatment compared to patients without baseline mutations (28% vs. 17%). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text